Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ania Fiksinski is active.

Publication


Featured researches published by Ania Fiksinski.


Schizophrenia Research | 2017

Autism Spectrum and psychosis risk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study

Ania Fiksinski; Elemi J. Breetvelt; Sasja N. Duijff; Anne S. Bassett; R.S. Kahn; Jacob Vorstman

BACKGROUNDnIndividuals with 22q11.2 deletion syndrome (22q11DS) have a 25% risk for schizophrenia and related psychotic disorders. Some have hypothesized that Autism Spectrum Disorders (ASDs) diagnosed in children with 22q11DS may actually represent the social-communicative defects often observed during the early developmental stages of schizophrenia.nnnMETHODSnWe prospectively studied 89 children with 22q11DS to test this hypothesis. At baseline, the Autism Diagnostic Interview was used to assess ASD, evaluating both current and early childhood behaviors. At follow-up, the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS) was used to determine development of a psychotic disorder or psychotic symptoms.nnnRESULTSnThe average age (±SD) at first and last assessments was 14.3±1.9 and 19.0±3.0years, respectively. Nineteen (21.3%) children developed a psychotic disorder. Contrary to our hypothesis, there was no significant difference in the proportion that developed a psychotic disorder, comparing those with (n=9, 17.3%) and those without ASD at baseline (n=10, 27%; OR=0.500, 95% CI=0.160-1.569, p=0.235). Similar results were obtained using autistic symptom severity as quantitative predicting variable, psychotic symptoms as the outcome, and when correcting for age, gender and full scale IQ.nnnCONCLUSIONnResults indicate that in children with 22q11DS, early childhood autistic features are not associated with an increased risk for subsequent development of psychotic disorders or symptoms, replicating previous retrospective findings in adults with 22q11DS. These results indicate that ASD and psychotic disorders can emerge independently, as pleiotropic phenotypes in the context of 22q11DS.


American Journal of Human Genetics | 2017

Nested Inversion Polymorphisms Predispose Chromosome 22q11.2 to Meiotic Rearrangements.

Wolfram Demaerel; Matthew S. Hestand; Elfi Vergaelen; Ann Swillen; Marcos López-Sánchez; Luis A. Pérez-Jurado; Donna M. McDonald-McGinn; Elaine H. Zackai; Beverly S. Emanuel; Bernice E. Morrow; Jeroen Breckpot; Koenraad Devriendt; Joris Vermeesch; Kevin M. Antshel; Celso Arango; Marco Armando; Anne S. Bassett; Carrie E. Bearden; Erik Boot; Marta Bravo-Sanchez; Elemi J. Breetvelt; Tiffany Busa; Nancy J. Butcher; Linda E. Campbell; Miri Carmel; Eva W.C. Chow; T. Blaine Crowley; Joseph F. Cubells; David J. Cutler; Maria Cristina Digilio

Inversion polymorphisms between low-copy repeats (LCRs) might predispose chromosomes to meiotic non-allelic homologous recombination (NAHR) events and thus lead to genomic disorders. However, for the 22q11.2 deletion syndrome (22q11.2DS), the most common genomic disorder, no such inversions have been uncovered as of yet. Using fiber-FISH, we demonstrate that parents transmitting the de novo 3 Mb LCR22A-D 22q11.2 deletion, the reciprocal duplication, and the smaller 1.5 Mb LCR22A-B 22q11.2 deletion carry inversions of LCR22B-D or LCR22C-D. Hence, the inversions predispose chromosome 22q11.2 to meiotic rearrangements and increase the individual risk for transmitting rearrangements. Interestingly, the inversions are nested or flanking rather than coinciding with the deletion or duplication sizes. This finding raises the possibility that inversions are a prerequisite not only for 22q11.2 rearrangements but also for all NAHR-mediated genomic disorders.


Neurology | 2018

Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2

Erik Boot; Nancy J. Butcher; Sean Udow; Connie Marras; Kin Y. Mok; Satoshi Kaneko; Matthew J. Barrett; Paolo Prontera; Brian D. Berman; Mario Masellis; Boris Dufournet; Karine Nguyen; Perrine Charles; Eugénie Mutez; Teodor Danaila; Aurélia Jacquette; Olivier Colin; Sophie Drapier; Michel Borg; Ania Fiksinski; Elfi Vergaelen; Ann Swillen; Annick Vogels; Annika Plate; Claudia Perandones; Thomas Gasser; Kristien Clerinx; Frédéric Bourdain; Kelly Mills; Nigel M. Williams

Objective To delineate the natural history, diagnosis, and treatment response of Parkinson disease (PD) in individuals with 22q11.2 deletion syndrome (22q11.2DS), and to determine if these patients differ from those with idiopathic PD. Methods In this international observational study, we characterized the clinical and neuroimaging features of 45 individuals with 22q11.2DS and PD (mean follow-up 7.5 ± 4.1 years). Results 22q11.2DS PD had a typical male excess (32 male, 71.1%), presentation and progression of hallmark motor symptoms, reduced striatal dopamine transporter binding with molecular imaging, and initial positive response to levodopa (93.3%). Mean age at motor symptom onset was relatively young (39.5 ± 8.5 years); 71.4% of cases had early-onset PD (<45 years). Despite having a similar age at onset, the diagnosis of PD was delayed in patients with a history of antipsychotic treatment compared with antipsychotic-naive patients (median 5 vs 1 year, p = 0.001). Preexisting psychotic disorders (24.5%) and mood or anxiety disorders (31.1%) were common, as were early dystonia (19.4%) and a history of seizures (33.3%). Conclusions Major clinical characteristics and response to standard treatments appear comparable in 22q11.2DS-associated PD to those in idiopathic PD, although the average age at onset is earlier. Importantly, treatment of preexisting psychotic illness may delay diagnosis of PD in 22q11.DS patients. An index of suspicion and vigilance for complex comorbidity may assist in identifying patients to prioritize for genetic testing.


Molecular Psychiatry | 2018

Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size

Daqiang Sun; Christopher Ching; Amy Lin; Jennifer K. Forsyth; Leila Kushan; Ariana Vajdi; Maria Jalbrzikowski; Laura Pacheco Hansen; Julio E. Villalon-Reina; Xiaoping Qu; Rachel Jonas; Therese van Amelsvoort; Geor Bakker; Wendy R. Kates; Kevin M. Antshel; Wanda Fremont; Linda E. Campbell; Kathryn McCabe; Eileen Daly; Maria Gudbrandsen; Clodagh Murphy; Declan Murphy; Michael Craig; Jacob Vorstman; Ania Fiksinski; Sanne Koops; Kosha Ruparel; David R. Roalf; Raquel E. Gur; J. Eric Schmitt

The 22q11.2 deletion (22q11DS) is a common chromosomal microdeletion and a potent risk factor for psychotic illness. Prior studies reported widespread cortical changes in 22q11DS, but were generally underpowered to characterize neuroanatomic abnormalities associated with psychosis in 22q11DS, and/or neuroanatomic effects of variability in deletion size. To address these issues, we developed the ENIGMA (Enhancing Neuro Imaging Genetics Through Meta-Analysis) 22q11.2 Working Group, representing the largest analysis of brain structural alterations in 22q11DS to date. The imaging data were collected from 10 centers worldwide, including 474 subjects with 22q11DS (ageu2009=u200918.2u2009±u20098.6; 46.9% female) and 315 typically developing, matched controls (ageu2009=u200918.0u2009±u20099.2; 45.9% female). Compared to controls, 22q11DS individuals showed thicker cortical gray matter overall (left/right hemispheres: Cohen’s du2009=u20090.61/0.65), but focal thickness reduction in temporal and cingulate cortex. Cortical surface area (SA), however, showed pervasive reductions in 22q11DS (left/right hemispheres: du2009=u2009−1.01/−1.02). 22q11DS cases vs. controls were classified with 93.8% accuracy based on these neuroanatomic patterns. Comparison of 22q11DS-psychosis to idiopathic schizophrenia (ENIGMA-Schizophrenia Working Group) revealed significant convergence of affected brain regions, particularly in fronto-temporal cortex. Finally, cortical SA was significantly greater in 22q11DS cases with smaller 1.5u2009Mb deletions, relative to those with typical 3u2009Mb deletions. We found a robust neuroanatomic signature of 22q11DS, and the first evidence that deletion size impacts brain structure. Psychotic illness in this highly penetrant deletion was associated with similar neuroanatomic abnormalities to idiopathic schizophrenia. These consistent cross-site findings highlight the homogeneity of this single genetic etiology, and support the suitability of 22q11DS as a biological model of schizophrenia.


Schizophrenia Research | 2018

Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome

Maria Niarchou; Samuel Chawner; Ania Fiksinski; Jacob Vorstman; Johanna Maeder; Maude Schneider; Stephan Eliez; Marco Armando; Maria Pontillo; Stefano Vicari; Donna M. McDonald-McGinn; Beverly S. Emanuel; Elaine H. Zackai; Carrie E. Bearden; Vandana Shashi; Stephen R. Hooper; Michael John Owen; Raquel E. Gur; Naomi R. Wray; Marianne Bernadette van den Bree; Anita Thapar

Individuals with 22q11.2 Deletion Syndrome (22q11.2DS) are at substantially heightened risk for psychosis. Thus, prevention and early intervention strategies that target the antecedents of psychosis in this high-risk group are a clinical priority. Attention Deficit Hyperactivity Disorder (ADHD) is one the most prevalent psychiatric disorders in children with 22q11.2DS, particularly the inattentive subtype. The aim of this study was to test the hypothesis that ADHD inattention symptoms predict later psychotic symptoms and/or psychotic disorder in those with 22q11.2DS. 250 children and adolescents with 22q11.2DS without psychotic symptoms at baseline took part in a longitudinal study. Assessments were performed using well-validated structured diagnostic instruments at two time points (T1 (mean ageu202f=u202f11.2, SDu202f=u202f3.1) and T2 (mean ageu202f=u202f14.3, SDu202f=u202f3.6)). Inattention symptoms at T1 were associated with development of psychotic symptoms at T2 (OR:1.2, pu202f=u202f0.01) but weak associations were found with development of psychotic disorder (OR:1.2, pu202f=u202f0.15). ADHD diagnosis at T1 was strongly associated with development of psychotic symptoms at T2 (OR:4.5, pu202f<u202f0.001) and psychotic disorder (OR:5.9, pu202f=u202f0.02). Our findings that inattention symptoms and the diagnosis of ADHD are associated with subsequent psychotic outcomes in 22q11.2DS have important clinical implications. Future studies examining the effects of stimulant and other ADHD treatments on individuals with 22q11.2DS are warranted.


American Journal of Medical Genetics Part A | 2018

Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome

Ania Fiksinski; Maude Schneider; Clodagh Murphy; Marco Armando; Stefano Vicari; Jaume M. Canyelles; Doron Gothelf; Stephan Eliez; Elemi J. Breetvelt; Celso Arango; Jacob Vorstman

The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene‐environment interactions, the age‐dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNVs will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.


American Journal of Medical Genetics Part A | 2018

Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects

Yingjie Zhao; Tingwei Guo; Ania Fiksinski; Elemi J. Breetvelt; Donna M. McDonald-McGinn; Terrence Blaine Crowley; Alexander Diacou; Maude Schneider; Stephan Eliez; Ann Swillen; Jeroen Breckpot; Joris Vermeesch; Eva W.C. Chow; Doron Gothelf; Sasja N. Duijff; Rens Evers; Therese van Amelsvoort; Marianne Bernadette van den Bree; Michael John Owen; Maria Niarchou; Carrie E. Bearden; Claudia Ornstein; Maria Pontillo; Antonino Buzzanca; Stefano Vicari; Marco Armando; Kieran C. Murphy; Clodagh Murphy; Sixto García-Miñaúr; Nicole Philip

The 22q11.2 deletion syndrome is caused by non‐allelic homologous recombination events during meiosis between low copy repeats (LCR22) termed A, B, C, and D. Most patients have a typical LCR22A‐D (AD) deletion of 3 million base pairs (Mb). In this report, we evaluated IQ scores in 1,478 subjects with 22q11.2DS. The mean of full scale IQ, verbal IQ, and performance IQ scores in our cohort were 72.41 (standard deviation‐SD of 13.72), 75.91(SD of 14.46), and 73.01(SD of 13.71), respectively. To investigate whether IQ scores are associated with deletion size, we examined individuals with the 3 Mb, AD (n = 1,353) and nested 1.5 Mb, AB (n = 74) deletions, since they comprised the largest subgroups. We found that full scale IQ was decreased by 6.25 points (p = .002), verbal IQ was decreased by 8.17 points (p = .0002) and performance IQ was decreased by 4.03 points (p = .028) in subjects with the AD versus AB deletion. Thus, individuals with the smaller, 1.5 Mb AB deletion have modestly higher IQ scores than those with the larger, 3 Mb AD deletion. Overall, the deletion of genes in the AB region largely explains the observed low IQ in the 22q11.2DS population. However, our results also indicate that haploinsufficiency of genes in the LCR22B‐D region (BD) exert an additional negative impact on IQ. Furthermore, we did not find evidence of a confounding effect of severe congenital heart disease on IQ scores in our cohort.


Psychological Medicine | 2017

White matter abnormalities in 22q11.2 deletion syndrome patients showing cognitive decline

Jasper Olivier Nuninga; Marc M. Bohlken; Sanne Koops; Ania Fiksinski; René C.W. Mandl; Elemi J. Breetvelt; Sasja N. Duijff; René S. Kahn; Iris E. Sommer; Jacob Vorstman


Psychological Medicine | 2018

Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia

Ania Fiksinski; Elemi J. Breetvelt; Y. J. Lee; Erik Boot; Nancy J. Butcher; Lisa Palmer; Eva W.C. Chow; René S. Kahn; Jacob Vorstman; Anne S. Bassett


Biological Psychiatry | 2018

S210. A Normative Chart for the Trajectory of Cognitive Functioning in a Genetically Selected Population: Longitudinal Findings From the International Brain and Behavior Consortium on 22q11.2 Deletion Syndrome

Ania Fiksinski; Jacob Vorstman; Anne S. Bassett; Elemi J. Breetvelt

Collaboration


Dive into the Ania Fiksinski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erik Boot

University Health Network

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nancy J. Butcher

Centre for Addiction and Mental Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Donna M. McDonald-McGinn

Children's Hospital of Philadelphia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge